B. Riley Securities left unchanged its top recommendation in digital health, naming LifeMD Inc. its highest-conviction idea following the firm s 26th Annual Institutional Investor Conference. The brokerage continues to rate the shares Buy with a $10 price target while the stock trades at $4.13.
Analysts at B. Riley characterize the recent market pullback in the stock as a buying opportunity, saying the core investment thesis remains intact. They add that a series of recent and prospective developments have broadened the set of near-term catalysts for the telehealth provider, increasing visibility on multiple revenue streams.
Commercial and pharmacy integration
Among the key items B. Riley highlighted is an exclusive telehealth collaboration between LifeMD and Antares tied to a direct-to-patient XYOSTED program. The firm describes this agreement as the first tangible evidence that LifeMD can capture branded pharmacy economics alongside its subscription-based care model. Under the arrangement, LifeMD will evaluate patients, dispense products from its own pharmacy, and fulfill orders, thereby collecting dispensing margin in addition to recurring subscription revenues from care.
B. Riley notes that capturing both dispensing margin and subscription revenue creates a separate, high-margin lane for the business and serves as proof of concept for monetizing branded therapies within LifeMD s platform.
Medicare GLP-1 coverage and patient economics
The Medicare GLP-1 Bridge, which launched July 1, received CMS guidance confirming reimbursement through Humana acting as the central processor for Wegovy, Zepbound KwikPen, and Foundayo with a $50 copay. B. Riley points out that this is the first occasion Medicare will reimburse GLP-1 medications for obesity, a development the firm expects will create new patient inflows without cannibalizing cash-pay volumes.
Crucially for LifeMD s unit economics, B. Riley emphasizes that insured patients typically deliver better financial returns. The firm cites roughly 50% lower customer acquisition costs for insured patients versus self-pay customers, along with a retention improvement of more than 10 percentage points for insured cohorts.
Regulatory and product-timing factors
B. Riley also flagged an upcoming FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24. The committee will consider adding seven peptides that were previously restricted onto the 503A bulks list. If the panel rules favorably, LifeMD could access another high-margin revenue opportunity tied to compounded therapies.
Looking further out, the firm expects next-generation GLP-1 launches from Novo Nordisk and Eli Lilly as potential market catalysts in 2026. B. Riley noted that Novo Nordisk s CagriSema might launch as soon as August, while Eli Lilly s retatrutide is projected by the firm to potentially reach the market in the fourth quarter of 2026. These product introductions could influence patient demand and the competitive landscape for GLP-1 therapies sold through telehealth channels.
Other growth vectors and recent corporate updates
B. Riley singled out LifeMD s women s health business as scaling toward a $20 million annualized run-rate exit by year-end, describing that revenue as among the highest-quality in the company s mix. In addition, LifeMD reported first-quarter 2026 results showing $50.2 million in revenue and earnings per share of -$0.20, both of which topped analyst estimates according to the firm s review.
Following the quarterly results, H.C. Wainwright reiterated its Buy rating on LifeMD, and the company appointed Umesh Sripad as its new Chief Technology Officer.
Investment takeaway
B. Riley remains constructive on LifeMD, retaining its top digital health pick status as the company pursues integrated pharmacy economics, benefits from newly available Medicare GLP-1 reimbursement, watches a pending FDA advisory committee outcome, and prepares for potential GLP-1 product introductions in 2026. The firm s view is supported by recent quarterly results and operational hires, with the stock currently trading significantly below the $10 target assigned by B. Riley.